Facebook
Twitter
LinkedIn
ForwardSubstance Use Harm Reduction and Medication-Assisted Treatment
Overview
| Registration |
|---|
Two attendance options:
|
Target Audience
DMU faculty, staff, students, residents, and the medical community.
Objectives
- Distinguish between Opioid Use Disorder and Harm Reduction with Medicated Assisted Treatment (MAT).
- Address stigma by the public and health providers.
- Describe the medications used in MAT.
- Recognize the importance of psychosocial support in treating the “whole” person with Substance Use Disorders.
- Review techniques for managing patients who are on MAT in various medical settings (Primary Care, Hospitalized, OTP) and the application of Harm Reduction techniques.
Educational Need
Drug overdose deaths have risen in the United States over the past two decades. Key findings from the National Vital Statistics System found that:
- In 2021, 106,699 drug overdose deaths occurred, resulting in an age-adjusted rate of 32.4 per 100,000 standard population in the United States.
- Adults aged 65 and over had the largest percentage increase in rates from 2020 through 2021.
- Drug overdose death rates increased for each race and Hispanic-origin group except non-Hispanic Asian people between 2020 and 2021.
- The rate of drug overdose deaths involving synthetic opioids other than methadone increased by 22%, while deaths involving heroin declined by 32% between 2020 and 2021.
- From 2020 through 2021, the rate of drug overdose deaths increased for deaths involving cocaine and those involving psychostimulants with abuse potential.
National Center for Health Statistics 2022. DOI: https://dx.doi.org/10.15620/cdc:122556.
Speakers
Heather Rice
Person in Recovery
Frank Filippelli, DO, PhD
Medical Director, UCS Healthcare
Session proposals are now being accepted for the DMU Grand Rounds series! Have you encountered an interesting clinical case, seen a patient with a unique history, condition, and/or treatment protocol, or been involved with interprofessional management that improves patient care and treatment outcomes? If so, you're invited to help build the series by submitting a session proposal! In addition to the rare and unique, cases of more common conditions are also acceptable, and proposals from external members of the broader healthcare community are welcomed and encouraged. Please click the button below to learn more about the series and access the submission form.
Location
Des Moines University’s new campus, located at 8025 Grand Avenue in West Des Moines, Iowa, offers an impressive 88 acres, providing ample space for growth and innovation. State-of-the-art facilities cater to the evolving needs of students and faculty, fostering an exceptional learning and research environment. The campus offers a perfect blend of academic excellence and access to the thriving community of Greater Des Moines, including cultural attractions, dining, and entertainment options.
CE Credits
Accreditation Statements
MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University (DMU) is accredited by the IMS to provide continuing medical education for physicians. DMU designates this live activity for 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this activity for a maximum of 1.0 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- DPM: Des Moines University (DMU) is approved by the Council on Podiatric Medical Education as a provider of continuing education in podiatric medicine. DMU has approved this activity for a maximum of 1.0 continuing education contact hours.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.0 continuing education contact hour(s). No partial credit awarded.
- Other healthcare providers: This live activity is designated for 1.0 AMA PRA Category 1 Credit(s)™.
Educational Grants
No ineligible company provided financial support for this continuing education activity.
DISCLOSURE
The speaker(s) will disclose if any pharmaceuticals, medical procedures, and devices discussed are investigational or unapproved by the U.S. Food and Drug Administration (FDA). The determination of educational content and the selection of speakers is the responsibility of the activity director.
Relevant to the content of this educational activity, the following individual(s) have no conflict(s) with ineligible companies to disclose.
- Frank Filippelli, DO, PhD - Speaker
- Heather Rice - Speaker
DISCLAIMER
The information provided at this activity is for continuing education purposes only. It is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
Available Credit
- 1.00 AMA PRA Category 1 Credits™
- 1.00 AOA Category 1A
- 1.00 CE Contact Hour(s)
- 1.00 CPME
- 1.00 IBON
Register/Take course
Price
There is no cost to attend, and all interested individuals are invited to participate.
Two attendance options:
- Des Moines University - No registration is necessary to attend on-site.
- Online - Register through Zoom.
If you're a student, do not register using your @student.dmu.edu email address. Zoom will reject the registration email confirmation. Please use your @dmu.edu email address.